In connection with this arrangement, XOMA paid a $1.5 million license fee to Servier in the third quarter of 2010. http://biz.yahoo.com/e/120117/xoma8-k.html That is even before the deal was signed. Terrible mistake to keep the secret that long.
Keeping it a secret for 16 months sounds strange. They are expecting FDA approval soon for the combination drug. Which is the central part of the deal. They sure would not pay 1.5 mil fee for 2 mil in sales. Maybe they waited for the FDA nod to make the announcement. That has to be the reason. It appears Xoma also made the Gevokizumab deal a lot earlier as well. Almost certainly at the same time. This makes sense since the 15 million for 052 never was right.